Jon Congleton

CEO Jon Congleton sold 75,000 shares for $1,960,601.40 via pre-arranged 10b5-1 plan at MLYS on 2026-06-30

Jon Congleton, CEO of Mineralys Therapeutics, executed 2 sales totaling 75,000 shares (75.0K shares) for $1,960,601.40 on 2026-06-30 at blended average price $26.14, reducing his holdings by 10.9% to 614,321 shares. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-30 and therefore scheduled rather than discretionary. The stock currently trades at $26.98, down 43.4% from its 52-week high of $47.65, and has declined 14.4% over the prior 30 days. The company reported negative net income of $-39,339,000.00 for the most recent full fiscal year. His prior 5 trades at MLYS show mixed subsequent performance, with 30-day and 90-day returns ranging from +4.5% to -10.2%, providing no clear directional pattern at this specific ticker.

CEO Congleton sold 75,000 shares (75.0K) for $1,970,521.82 on 2026-03-31; prior 5 same-ticker sells all showed negative 90d returns

Jon Congleton, CEO of Mineralys Therapeutics, executed 3 separate sales totaling 75,000 shares for $1,970,521.82 on 2026-03-31, reducing his holdings to 705,051 shares (705.1K shares). His prior trades at MLYS show a consistent pattern: all 5 preceding trades were sells, and the 3 that are measurable at the 90-day mark (2025-11-11 sales) posted declines of -30.8%, -29.8%, and -27.0%, reflecting a 100% well-timed rate at this ticker. The company is unprofitable with a net income of $-36,932,000.00 ($-36.9M) over its most recent full fiscal year. The stock currently trades at $26.97, down 43.0% from its 52-week high of $47.33 and down 5.4% over the past 30 days.

CEO Congleton sells 16,236 shares at $32.21–$33.15 for $529,639.60; stock down -24.0% in 90 days amid -$36.9M net loss

CEO Jon Congleton executed 2 separate sales totaling 16,236 shares on 2026-01-12, raising $529,639.60 at prices of $32.21 and $33.15 per share, representing a -2.5% reduction in his 655,387-share holdings. The timing is material: the stock has declined -24.0% over the prior 90 days and -30.4% from its 52-week high of $47.33, and the company reported a net loss of -$36,932,000 for its most recent fiscal year. His prior transaction history at Mineralys—5 sells on 2025-11-11—showed 30-day declines ranging from -13.4% to -23.1%, while the underlying business remains unprofitable. This sale by the CEO occurs against a backdrop of sustained downward momentum and negative fundamentals, providing context for understanding the company's current market position and insider activity.

CEO Jon Congleton sells 200,000 shares ($9.1M) across 6 transactions at blended avg $45.44; reduces stake 24.1%

CEO Jon Congleton executed 6 separate sales totaling 200,000 shares for $9,088,498.87 on 2025-11-11, reducing his holdings from 831,305 shares to 631,305 shares. The transaction occurred near the stock's 52-week high (currently trading at $44.29, -6.4% from the $47.33 peak), and his prior sales at this ticker have demonstrated a 100% well-timed pattern at the 90-day mark across 3 measurable prior trades. Notably, Mineralys is unprofitable with net income of $-36,932,000.00 for its most recent full fiscal year, which frames the large discretionary share liquidation against weak underlying fundamentals. The magnitude of the sale ($9.1M, representing a -24.1% reduction in pre-transaction holdings) is material and warrants attention to whether market conditions or company developments are prompting substantial executive exposure reduction.

MLYS CEO Congleton sold 15,100 shares for $644,326.87 on 2025-10-13 at $42.67 avg; 5 of 5 prior MLYS sales well-timed (negative 90d returns)

CEO Jon Congleton executed 2 separate sales totaling 15,100 shares for $644,326.87 on 2025-10-13, reducing holdings by 1.8% to 831,305 shares. This sale occurs at $42.67 (blended average), near the 52-week high of $43.35, following a 202.3% surge over 90 days. Notably, Congleton's prior trading pattern at MLYS shows all 5 prior sales were well-timed, with each followed by negative 90-day returns (ranging from -0.3% to -8.6%), suggesting consistent predictive accuracy in identifying local peaks. Against this backdrop, the current sale near all-time highs warrants attention, particularly given the company's unprofitability ($-43.3M net income) and the stock's extreme recent momentum.

CEO Congleton sells 49.3K shares across 3 trades (Jun 17-20) for $592.0K; stock down 9.3% in 30 days amid unprofitable operations

Mineralys CEO Jon Congleton executed 3 separate sales totaling 49,313 shares for $592,022.00 across June 17-20 at prices ranging from $11.73 to $12.25, reducing his holdings by 5.1% to 926,958 shares. The blended average sale price of $12.01 is 2.6% above the current price of $11.71, and the company's stock has declined 9.3% over the trailing 30 days and 31.5% from its 52-week high of $17.10. Notably, the company posted a full-year net loss of $-31,508,000.00 and remains unprofitable, establishing a backdrop of operational headwinds. The timing of this multi-tranche sale—occurring as the stock weakened and following two prior sales on June 13-14 (also recently filed and not yet measurable in outcome)—occurs against a deteriorating price trend and negative fundamental backdrop.

CEO Jon Congleton sold 72,797 shares over 3 days (June 12–14) for $924,203.22, reducing holdings 6.9%; stock currently -26.4% from 52-week high.

Jon Congleton, Chief Executive Officer of Mineralys Therapeutics, executed 3 separate sales totaling 72,797 shares for $924,203.22 at a blended average price of $12.70 on June 12–14, 2024. This sale reduced his holdings by 6.9% to 976,271 shares. The timing warrants attention: while the transaction prices ($12.52–$12.77) were modest relative to the 52-week high of $17.10, the stock has since declined further to $12.58 (a -26.4% retreat from peak), and the company operates unprofitably with net income of $-31,508,000. His prior MLYS purchases showed mixed execution—one delivered a 90-day return of +156.4%, but three others returned -4.9%, -8.1%, and -19.2% at the 30-day mark, suggesting inconsistent timing of entry decisions at this ticker. This filing reflects a discrete liquidation rather than a pattern-driven reposition.